Based on the Carasent ASA stock forecast from 0 analysts, the average analyst target price for Carasent ASA is not available over the next 12 months. Carasent ASA’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Carasent ASA is Neutral, which is based on 0 positive signals and 0 negative signals. At the last closing, Carasent ASA’s stock price was NOK 14.44. Carasent ASA’s stock price has changed by +6.57% over the past week, -5.12% over the past month and -22.00% over the last year.
No recent analyst target price found for Carasent ASA
No recent average analyst rating found for Carasent ASA
Company Overview Carasent ASA
Carasent ASA provides cloud-based medical record services to the health care industry in the Nordic region. The company offers Webdoc, a digital electronic health record (EHR) system; Vårdrummet, a digital platform for communication between patients and therapists, as well as care givers; and Ad Curis, a journal and professional system that delivers forward-thinking services to rehabilitation, substance abuse treatment, and mental health care, as well as organizations within upbringing and preventive works. It also provides Metodika EPM, a solution for medium sized private clinics and hospitals; Medrave M4, a program that offers healthcare professionals with an overview of the patient treatment group; Confrere, a video solution for physicians; and Plustoo, a software solution that collects, analyses, and visualizes data, as well as enables occupational health providers, employers, and employees to collaborate for healthy and sustainable work environment. In addition, the company provides Ad Voca; and Ad Opus, a system that structures work processes to follow-up participants in a course of measures for companies that work with inclusion into working life. Carasent ASA was formerly known as Apptix ASA and changed its name to Carasent ASA in May 2019. The company was founded in 1997 and is based in Oslo, Norway. Address: Oevre Slottsgate 2B, Oslo, Norway, 0157 Read Less
Carasent ASA provides cloud-based medical record services to the health care industry in the Nordic region. The company offers Webdoc, a digital electronic health record (EHR) system; Vårdrummet, a digital platform for communication between patients and therapists, as well as ca...Read More
Frequently Asked Questions About Carasent ASA (0H9M:LSE) Stock
Stock Target Advisor's fundamental analysis for Carasent ASA's stock is Neutral.
Unfortunately we do not have enough data on 0H9M:LSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 0H9M:LSE's stock to indicate what its average analyst target is.
0H9M:LSE stock's Price/Earning ratio is 0.28.
Based on this 0H9M:LSE may be a overvalued for its sector.
The last closing price of 0H9M:LSE's stock was NOK 14.44.
Unfortunately we do not currently have any market capitalization data for 0H9M:LSE's stock.
Unfortunately we do not have enough analyst data on 0H9M:LSE's stock to indicate whether its price will go up or not.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
There is nothing we particularly dislike
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 0H9M:LSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
